9/13/2021 8:26:31 AM
Outlook Therapeutics Presents Positive NORSE THREE Safety Data For ONS-5010/LYTENAVA At EURETINA 2021 Medical Conference
5/14/2021 8:13:51 AM
Outlook Therapeutics Q2 Net Loss Attributable $13.1 Mln Or $0.09/Shr Vs Loss $17.5 Mln Or $0.36/Shr Year-ago
3/31/2021 8:29:18 AM
Outlook Therapeutics Reports Positive Safety Profile From NORSE THREE Open-Label Safety Study For ONS-5010 / LYTENAVA
1/29/2021 12:38:37 AM
Outlook Therapeutics Increase Size Of Public Offering And Purchase On Firm Commitment Basis 35 Mln Shares At $1/Shr
8/26/2020 8:11:57 AM
Outlook Therapeutics Reports Topline Results And Positive Proof-of-Concept For ONS-5010 / LYTENAVA From NORSE 1
7/7/2020 8:08:14 AM
Outlook Therapeutics Completes Patient Enrollment In NORSE 2 Clinical Trial For ONS-5010 / LYTENAVA
6/17/2020 8:12:42 AM
Outlook Therapeutics Provides Clinical Update On ONS-5010 / LYTENAVA
4/14/2020 8:25:46 AM
Outlook Therapeutics Provides COVID-19 Impact Update On Impact Of The COVID-19 Pandemic On Status Of NORSE 1 And NORSE 2
2/24/2020 8:07:16 AM
Outlook Therapeutics Reports $10.2 Mln Financings Priced At-The-Market
1/28/2020 8:22:22 AM
Outlook Therapeutics Enters Agreements With BioLexis